Vivid Dx
Develops AI healthcare solutions that help hospitals address drug-resistant infections, a major challenge in modern medicine.
Overview
Vivid Dx is an AI healthcare company focused on helping hospitals confront drug-resistant infections. Its offering is positioned for clinical providers facing antimicrobial resistance, described in its funding announcement as one of modern medicine’s most urgent threats. The company raised $15 million in an undisclosed round announced on July 28, 2026, representing its reported total funding across one round. The financing reflects investor interest in hospital-focused technologies for infection-related challenges.
Funding History
Vivid Dx Raises $15M to Help Hospitals Confront One of Modern Medicine's Most Urgent Threats: Drug-Resistant Infections
Frequently Asked Questions
- How much has Vivid Dx raised in total?
- Vivid Dx has raised a total of $15M across 1 funding round.
- What does Vivid Dx do?
- Vivid Dx is an AI healthcare company focused on helping hospitals confront drug-resistant infections. Its offering is positioned for clinical providers facing antimicrobial resistance, described in its funding announcement as one of modern medicine’s most urgent threats. The company raised $15 million in an undisclosed round announced on July 28, 2026, representing its reported total funding across one round. The financing reflects investor interest in hospital-focused technologies for infection-related challenges.
- Where is Vivid Dx headquartered?
- Vivid Dx is headquartered in San Francisco, CA.
Related Insights
A comprehensive analysis of Sage's funding history, investors, competitive position, and growth trajectory in the AI Healthcare space.
A data-driven analysis of AI funding across all 17 sectors — from Foundation Models to AI Healthcare — with sector totals, deal counts, top companies, and investment trends for 2026.
A comprehensive, data-driven analysis of AI venture funding in Q1 2026. $35.9 billion raised across 95 deals, with 15 mega-rounds capturing 85.5% of total capital. Europe breaks out with $6.65B, and billion-dollar seed rounds arrive for the first time.